mega swerte

Social Media Analytics Market Comprehensive Overview and Forecast 2024-2031 11-30-2024 06:11 PM CET | IT, New Media & Software Press release from: SkyQuest Technology The Social Media Analytics Market is experiencing rapid growth, fueled by advancements in hardware, software, and digital infrastructure. With services spanning cloud computing, cybersecurity, data analytics, and artificial intelligence, the market is at the forefront of digital transformation across industries. Emerging technologies such as 5G, blockchain, and IoT are unlocking unprecedented opportunities, driving innovation and expansion. Get a Free Sample Report With Table Of Contents: https://www.skyquestt.com/sample-request/social-media-analytics-market Market Size and Growth: Social Media Analytics Market size was valued at USD 4.38 Billion in 2022 and is poised to grow from USD 4.79 Billion in 2023 to USD 9.83 Billion by 2031, at a CAGR of 9.4% during the forecast period (2024-2031). The most valuable investment indicators are insights into key market trends, making it easier for potential participants to make informed decisions. The research seeks to identify numerous growth opportunities that readers can consider and capitalize on by utilizing all the relevant information. By closely analyzing critical factors that influence growth, such as pricing, production, profit margins, and value chain dynamics, future market expansion can be predicted with greater precision. Key Market Players: IBM Corporation (US) Salesforce.com, Inc. (US) Adobe Inc. (US) SAS Institute Inc. (US) Oracle Corporation (US) NetBase Quid (US) Talkwalker Inc. (Luxembourg) Sprout Social, Inc. (US) Hootsuite Inc. (Canada) Meltwater (Norway) Digimind (France) Keyhole Inc. (Canada) Social Status (Australia) Rival IQ (US) = Region-wise Market Insights The regional analysis offers detailed breakdowns of revenue, sales, and market share for key geographies. This section includes future growth projections, pricing strategies, and other critical metrics. Regions covered in the report: North America: United States, Canada, Mexico Europe: Germany, France, UK, Russia, Italy Asia-Pacific: China, Japan, Korea, India, Southeast Asia South America: Brazil, Argentina, Colombia Middle East & Africa: Saudi Arabia, UAE, Egypt, Nigeria, South Africa For Personalized Insights, Speak with Our Experts: https://www.skyquestt.com/speak-with-analyst/social-media-analytics-market Segments covered in the Social Media Analytics Market include: Offering Solution [Software Type (Social Listening and Monitoring, Social Media Marketing, Social Media Advertising Software, Social Media Management Software, and Others), deployment type {Cloud (Public, Private, and Hybrid), On premises}, services {professional services (Consulting Services, Deployment and Integration, Support and Maintenance), Managed Services}] Application Sales and Marketing Management, Customer Experience Management, Competitive Intelligence, Risk Management and Fraud Detection, Public Safety and Law Enforcement, and Others Social Media Analytics Market Size and Scope The Social Media Analytics market has shown significant growth in recent years, fueled by rising demand for power electronics across industries such as automotive, telecommunications, and renewable energy. This market is set to grow further as the global adoption of electric vehicles and renewable energy increases. Social Media Analytics are highly valued for their superior thermal conductivity, electrical insulation, and mechanical strength, making them essential components in power modules and electronic devices. With ongoing technological and manufacturing advancements, the applications of Social Media Analytics are expected to expand, encompassing a broader range of uses in the near future. For a Comprehensive Report on the Social Media Analytics Market 2024, Visit: https://www.skyquestt.com/report/social-media-analytics-market Frequently Asked Questions What are the key global trends influencing the market? Who are the top manufacturers, and what are their strategies? How is the market evolving across regions? What are the major challenges and opportunities in the Social Media Analytics Market? About Us: SkyQuest is an IP-focused Research and Investment Bank and Technology Accelerator. We offer access to technologies, markets, and financing across sectors like Life Sciences, CleanTech, AgriTech, NanoTech, and Information & Communication Technology. We collaborate closely with innovators, entrepreneurs, companies, and investors to help them leverage external R&D sources and optimize the economic potential of their intellectual assets. Our expertise in innovation management and commercialization spans North America, Europe, ASEAN, and Asia Pacific. Contact: Mr. Jagraj Singh Skyquest Technology 1 Apache Way, Westford, Massachusetts 01886, USA (+1) 351-333-4748 Visit our website: Skyquest Technology This release was published on openPR.

THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE AmgenWOONSOCKET, R.I. , Dec. 16, 2024 /PRNewswire/ -- CVS Health Corporation ("CVS Health" or the "Company," NYSE: CVS) announced today the applicable Reference Yields and Total Consideration (each as summarized in the tables below) to be paid in connection with the previously announced cash tender offer (the "Maximum Tender Offer" ) for the maximum principal amount of the following series of Maximum Tender Offer Notes (as defined below) for which the aggregate purchase price, not including Accrued Interest (as defined below), payable in respect of such Maximum Tender Offer Notes, does not exceed $1,774,423,242.62 (such maximum purchase price, the "Maximum Tender Offer Amount"): its 2.700% Senior Notes due 2040, the 3.875% Senior Notes due 2047 issued by its wholly-owned subsidiary Aetna Inc. ("Aetna"), its 4.250% Senior Notes due 2050, the 4.125% Senior Notes due 2042 issued by Aetna, its 4.125% Senior Notes due 2040, its 2.125% Senior Notes due 2031, its 1.875% Senior Notes due 2031, its 5.050% Senior Notes due 2048, the 4.500% Senior Notes due 2042 issued by Aetna and its 1.750% Senior Notes due 2030 (together, the "Maximum Tender Offer Notes"). The applicable Reference Yield for the Maximum Tender Offer Notes and the Total Consideration for the Maximum Tender Offer Notes are summarized in the table below: Maximum Tender Offer Notes : Title of Notes CUSIP Number Original Issuer Principal Amount Outstanding Maturity Date Acceptance Priority Level (1) UST Reference Security Bloomberg Reference Page Fixed Spread (bps) Early Tender Payment (2) Reference Yield (3) Total Consideration (2)(3) Approximate Proration Factor (4) 2.700% Senior Notes due 2040 126650DP2 CVS Health Corporation $1,250,000,000 8/21/2040 1 4.625% due 11/15/2044 FIT1 +110 bps $30 4.676 % $685.54 100 % 3.875% Senior Notes due 2047 00817YAZ1 Aetna Inc. $1,000,000,000 8/15/2047 2 4.625% due 11/15/2044 FIT1 +121 bps $30 4.676 % $750.06 100 % 4.250% Senior Notes due 2050 126650DL1 CVS Health Corporation $750,000,000 4/1/2050 3 4.250% due 8/15/2054 FIT1 +136 bps $30 4.611 % $776.80 100 % 4.125% Senior Notes due 2042 00817YAM0 Aetna Inc. $500,000,000 11/15/2042 4 4.625% due 11/15/2044 FIT1 +122 bps $30 4.676 % $805.69 100 % 4.125% Senior Notes due 2040 126650DK3 CVS Health Corporation $1,000,000,000 4/1/2040 5 4.625% due 11/15/2044 FIT1 +119 bps $30 4.676 % $825.77 57.5 % 2.125% Senior Notes due 2031 126650DR8 CVS Health Corporation $1,000,000,000 9/15/2031 6 4.250% due 11/15/2034 FIT1 +92 bps $30 N/A N/A 0 % 1.875% Senior Notes due 2031 126650DQ0 CVS Health Corporation $1,250,000,000 2/28/2031 7 4.250% due 11/15/2034 FIT1 +87 bps $30 N/A N/A 0 % 5.050% Senior Notes due 2048 126650CZ1 CVS Health Corporation $8,000,000,000 3/25/2048 8 4.250% due 8/15/2054 FIT1 +156 bps $30 N/A N/A 0 % 4.500% Senior Notes due 2042 00817YAJ7 Aetna Inc. $500,000,000 5/15/2042 9 4.625% due 11/15/2044 FIT1 +130 bps $30 N/A N/A 0 % 1.750% Senior Notes due 2030 126650DN7 CVS Health Corporation $1,250,000,000 8/21/2030 10 4.125% due 11/30/2029 FIT1 +106 bps $30 N/A N/A 0 % (1) Subject to each of the Maximum Tender Offer Amount and proration, the principal amount of each series of Maximum Tender Offer Notes that is purchased in the Maximum Tender Offer will be determined in accordance with the applicable acceptance priority level (in numerical priority order) specified in this column. (2) Per $1,000 principal amount of Maximum Tender Offer Notes validly tendered at or prior to the Early Tender Date (as defined below) and accepted for purchase. (3) Pricing information has only been provided for the Maximum Tender Offer Notes that are expected to be fully or partially accepted for tender. (4) The proration factor has been rounded to the nearest tenth of a percentage point for presentation purposes. The Maximum Tender Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated December 2, 2024 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), which sets forth a more detailed description of the Maximum Tender Offer. Copies of the Offer to Purchase are available at www.dfking.com/cvs . The Maximum Tender Offer is open to all registered holders (individually, a "Holder" and collectively, the "Holders") of the Maximum Tender Offer Notes. The Total Consideration payable by CVS Health for the Maximum Tender Offer Notes is a price per $1,000 principal amount calculated as described in the Offer to Purchase in a manner intended to result in a yield to maturity or first par call date, as the case may be, equal to the sum of the yield to maturity of the applicable U.S. Treasury reference security specified in the table above as determined at 10:00 a.m. , New York City time, on December 16, 2024 and the applicable fixed spread shown in the table above. Maximum Tender Offer Notes that were tendered and not validly withdrawn at or prior to 5:00 p.m. , New York City time, on December 13, 2024 (the "Early Tender Date") and that are accepted for purchase will receive the applicable Total Consideration, which includes the Early Tender Payment (as defined in the Offer to Purchase). Maximum Tender Offer Notes that are tendered after the Early Tender Date but at or prior to 5:00 p.m. , New York City time, on December 31, 2024 (the "Maximum Tender Offer Expiration Date") (unless earlier terminated by CVS Health as described in the Offer to Purchase) and that are not validly withdrawn and that are accepted for purchase will receive only the applicable Tender Offer Consideration (as defined in the Offer to Purchase), which is the applicable Total Consideration minus the Early Tender Payment. The Maximum Tender Offer Withdrawal Deadline of 5:00 p.m. , New York City time, on December 13, 2024 has passed and, accordingly, Maximum Tender Offer Notes validly tendered in the Maximum Tender Offer may no longer be withdrawn. The settlement date for the Maximum Tender Offer Notes validly tendered at or prior to the Early Tender Date and accepted for purchase is expected to be December 18, 2024 , the third business day after the Early Tender Date (the "Early Settlement Date"). Although the Maximum Tender Offers is scheduled to expire at 5:00 p.m. , New York City time, on December 31, 2024 , unless extended or terminated, because the aggregate purchase price of Notes validly tendered (and not validly withdrawn) prior to the Early Tender Date exceeded the Maximum Tender Offer Amount, there is not expected to be a Final Settlement Date (as defined in the Offer to Purchase), and no Notes tendered after the Early Tender Date are expected to be accepted for purchase. In addition to the Total Consideration for the Maximum Tender Offer Notes, Holders of the Maximum Tender Offer Notes accepted for purchase on the Early Settlement Date will receive accrued and unpaid interest ("Accrued Interest") on those Maximum Tender Offer Notes from the last interest payment date with respect to those Maximum Tender Offer Notes to, but not including, the Early Settlement Date. CVS Health expressly reserves the right, in its sole discretion, subject to applicable law, to amend, extend or terminate the Maximum Tender Offer with respect to any or all series of Maximum Tender Offer Notes at any time if any condition to the Maximum Tender Offer is not satisfied. The Maximum Tender Offer is not conditioned on any minimum principal amount of Maximum Tender Offer Notes being tendered but the Maximum Tender Offer is subject to certain other general conditions as described in the Offer to Purchase. CVS Health has retained Barclays Capital Inc. and Mizuho Securities USA LLC to act as Dealer Managers for the Maximum Tender Offer. D.F. King & Co., Inc. has been retained to act as the Tender and Information Agent for the Maximum Tender Offer. The Offer to Purchase may be accessed at the following link: http://www.dfking.com/cvs . Requests for assistance relating to the procedures for tendering Maximum Tender Notes may be directed to the Tender and Information Agent either by email at cvs@dfking.com , or by phone (212) 269-5550 (for banks and brokers only) or (800) 487-4870 (for all others toll free). Requests for assistance relating to the terms and conditions of the Maximum Tender Offer may be directed to Barclays Capital Inc. at (800) 438-3242 (toll free) or (212) 528-7581 (collect) or Mizuho Securities USA LLC at (866) 271-7403 (toll-free) or (212) 205-7741. Beneficial owners may also contact their broker, dealer, commercial bank, trust company or other nominee for assistance. This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to, any securities, including the Maximum Tender Offer Notes. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Maximum Tender Offer is being made solely pursuant to the Offer to Purchase made available to Holders of the Maximum Tender Offer Notes. None of CVS Health, the Dealer Managers, Tender and Information Agent or the trustees with respect to the Maximum Tender Offer Notes, or any of their respective affiliates, is making any recommendation as to whether or not Holders should tender or refrain from tendering all or any portion of their Maximum Tender Offer Notes in response to the Maximum Tender Offer. Holders are urged to evaluate carefully all information in the Offer to Purchase, consult their own investment and tax advisers and make their own decisions whether to tender Maximum Tender Offer Notes in the Maximum Tender Offer, and, if so, the principal amount of Maximum Tender Offer Notes to tender. About CVS Health CVS Health is a leading health solutions company building a world of health around every consumer it serves and connecting care so that it works for people wherever they are. As of September 30, 2024 , the Company had more than 9,000 retail locations, more than 900 walk-in medical clinics, more than 225 primary care medical clinics, a leading pharmacy benefits manager with approximately 90 million plan members and expanding specialty pharmacy solutions, and a dedicated senior pharmacy care business serving more than 800,000 patients per year. The Company also serves an estimated more than 36 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company is creating new sources of value through its integrated model allowing it to expand into personalized, technology driven care delivery and health services, increasing access to quality care, delivering better health outcomes and lowering overall health care costs. Forward-Looking Statements This press release contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024 , June 30, 2024 and September 30, 2024 and our Current Reports on Form 8-K. You are cautioned not to place undue reliance on CVS Health's forward-looking statements. CVS Health's forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise. Investor Larry McGrath Media Ethan Slavin Contact: Executive Vice President Contact: 860-273-6095 Chief Strategy Officer & Chief Strategic Advisor to the CEO investorinfo@cvshealth.com Ethan.Slavin@CVSHealth.com View original content to download multimedia: https://www.prnewswire.com/news-releases/cvs-health-corporation-announces-pricing-of-maximum-tender-offer-302333016.html SOURCE CVS Health

Suspect in the killing of UnitedHealthcare’s CEO struggles, shouts while entering courthouseTrinity Jubilee Center breaks ground on $5.1 million building in Lewiston to serve the needy

NonePeak XV, Bisque and Link Investment Trust will together sell a 12.2% stake, or 85.8 Lakh shares, in Awfis The investors will offload the shares at INR 680 apiece. This represents a discount of 5.2% to the stock’s closing price of INR 717.05 on Tuesday As of September 2024, Peak XV held a 10.92% stake in Awfis. Bisque and Link Investment Trust owned 14.38% and 0.36% stakes, respectively VC major Peak XV Partners, Mauritius-based investment firm Bisque Limited, and Delhi-based Link Investment Trust reportedly plan to offload Awfis shares worth INR 583 Cr. Citing sources, CNBC-TV18 reported that the three investors will together offload a 12.2% stake, or 85.8 Lakh shares, in the flexible workspace solutions company via a block deal. As per the report, the investors will offload the shares at INR 680 apiece. This represents a discount of 5.2% to the stock’s closing price of INR 717.05 on Tuesday. According to a separate NDTV Profit report, IIFL Capital Services and ICICI Securities are the book runners for the deal. As of September 2024, promoter Peak XV held a 10.92% stake in the coworking space provider, while Bisque and Link Investment Trust owned 14.38% and 0.36% stake in Awfis, respectively. Shares of Awfis are down 7.5% in the past month but up over 70% since its listing in May. Meanwhile, brokerages continue to be bullish on the company, with as many as five analysts tracking the company having a ‘BUY’ rating on the stock. The positive outlook comes largely on the back of Awfis rapidly expanding its footprint and signing new office spaces. Last month, the company announced that it would design and manage 1.65 Lakh sq ft of office space in Mumbai for the National Stock Exchange. Founded in 2015 by Amit Ramani, Awfis claims to be the largest flexible space operator in India with 181 centres, around 1.1 Lakh seats, and about 5.6 Mn square feet of chargeable area, as of March 2024. The company started operations as a coworking network, and has since expanded into the tech-enabled workspace solutions segment. It reported a consolidated net profit of INR 38.67 Cr in the second quarter (Q2) of the financial year 2024-25 (FY25). In contrast, it posted a net loss of INR 4.34 Cr in Q2 FY24. Operating revenue jumped 40.46% to INR 292.38 Cr during the quarter under review from INR 208.15 Cr in Q2 FY24. Shares of Awfis closed Tuesday (December 10) trading session 0.15% lower at INR 716.95 on the BSE.

President-elect Donald Trump joined SoftBank Group CEO Masayoshi Son to announce plans by the Japanese company to invest $100 billion in U.S. projects over the next four years. Trump announced the planned investments, which are expected to focus on artificial intelligence, at his Mar-a-Lago resort on Monday, with Son at his side, along with Howard Lutnick, head of investment bank Cantor Fitzgerald and Trump’s pick for commerce secretary. “He’s doing this because he feels very optimistic about our country,” Trump said. The president-elect said that since his election, people have expressed interest in “coming in with tremendous amounts of money." The investments by SoftBank, Trump said, are “a monumental demonstration of confidence in America’s future.” Son said he wanted to “celebrate the great victory of President Trump” and that he will “bring the world into peace again.” “I am truly excited to make this happen,” he said. After the president-elect noted the $100 billion was double an investment pledge Son made in 2016 on the eve of Trump's first administration, the technology mogul said he was doubling down. Trump, appearing to joke, asked him at the microphone if he would double the investment again: “Would you make it $200 billion?” Trump has in the past announced deals with companies overseas with much fanfare, though some companies in the end failed to deliver on those promised investments. Foxconn Technology Group, a Taiwanese company best known for producing Apple iPhones, won Trump's praise after announcing plans in 2017 to build a $10 billion complex that would employ 13,000 people in a small town just south of Milwaukee. But Foxconn's investment has been scaled back to a fraction of that after the COVID-19 pandemic. Monday's announcement, however, is a win for Trump, who has used the weeks since the election to promote his policies, negotiate with foreign leaders and try to strike deals. He had already threatened steep tariffs for Mexico and Canada, which prompted a visit from Canada’s prime minister aIn a post on his Truth Social site last week, Trump said anyone making a $1 billion investment in the United States “will receive fully expedited approvals and permits, including, but in no way limited to, all Environmental approvals.”nd a call with Mexico's president. SoftBank was founded in 1981 by Son, a brash entrepreneur who studied at the University of California, Berkeley. SoftBank makes investments in a variety of companies that it groups together through its capital venture fund. The company's investment portfolio includes search engine Yahoo, Chinese retailer Alibaba, and artificial intelligence company Nvidia. Earlier this year, it joined a partnership with Saudi Arabia to build a robot factory in Riyadh. After Trump won the White House the first time in 2016, he met with Son before taking office. Son then announced plans to create 50,000 jobs and invest $50 billion in U.S. startups, which Trump celebrated on social media, saying it never would have happened if he hadn’t won the election. Not all investments have panned out. The most notorious was SoftBank's massive stake in the office-sharing company WeWork which sought bankruptcy protection last year. It also invested in the failed robot pizza-making company Zume. Monday's announcement comes days after Trump vowed to expedite federal permits for energy projects and other construction worth more than $1 billion. Associated Press writers Jill Colvin in New York, along with Paul Wiseman and Zeke Miller in Washington, contributed to this story.